Literature DB >> 26054430

Confetti-like depigmentation: A potential sign of rapidly progressing vitiligo.

Juan Jesús Sosa1, Sharif D Currimbhoy1, Uzoamaka Ukoha1, Samantha Sirignano1, Ryan O'Leary2, Travis Vandergriff1, Linda S Hynan3, Amit G Pandya4.   

Abstract

BACKGROUND: Confetti-like depigmentation was noted in patients reporting recent worsening of vitiligo.
OBJECTIVE: We sought to determine if confetti-like depigmentation is a marker of rapidly progressing vitiligo.
METHODS: Review of patient records and images of patients from a vitiligo registry resulted in 7 patients with 12 images that fit inclusion criteria and were evaluated for percent depigmentation by 3 independent reviewers. The Vitiligo Disease Activity Score and the Koebner Phenomenon in Vitiligo Score in an additional cohort of patients with confetti-like lesions were compared with patients who had vitiligo without confetti-like lesions.
RESULTS: The mean percentage of depigmentation at baseline was 19.2%, which increased to 43.9% in images obtained at a mean of 16 weeks of follow-up. Vitiligo Disease Activity Score and Koebner Phenomenon in Vitiligo Score were significantly higher in the patients with confetti-like lesions compared with those without confetti-like lesions. A skin biopsy specimen of a confetti-like lesion in 1 patient revealed an inflammatory infiltrate in the papillary dermis with CD8(+) T cells localized to the dermoepidermal junction. LIMITATIONS: Small, single-center retrospective review and lack of full-body photographs are limitations.
CONCLUSIONS: A confetti-like pattern of depigmentation may be a negative prognostic indicator for patients with rapidly progressing vitiligo. Further, prospective studies to evaluate this physical finding should be performed.
Copyright © 2015 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  depigmentation; leukoderma; melanocyte; pigmentation; skin of color; vitiligo

Mesh:

Year:  2015        PMID: 26054430     DOI: 10.1016/j.jaad.2015.05.014

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  11 in total

Review 1.  Chemical-Induced Vitiligo.

Authors:  John E Harris
Journal:  Dermatol Clin       Date:  2017-04       Impact factor: 3.478

2.  Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.

Authors:  Lucy Y Liu; James P Strassner; Maggi A Refat; John E Harris; Brett A King
Journal:  J Am Acad Dermatol       Date:  2017-08-18       Impact factor: 11.527

3.  Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo.

Authors:  Nesrine Boukhedouni; Christina Martins; Anne-Sophie Darrigade; Claire Drullion; Jérôme Rambert; Christine Barrault; Julien Garnier; Clément Jacquemin; Denis Thiolat; Fabienne Lucchese; Franck Morel; Khaled Ezzedine; Alain Taieb; François-Xavier Bernard; Julien Seneschal; Katia Boniface
Journal:  JCI Insight       Date:  2020-06-04

4.  Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity.

Authors:  James P Strassner; Mehdi Rashighi; Maggi Ahmed Refat; Jillian M Richmond; John E Harris
Journal:  J Am Acad Dermatol       Date:  2017-03-01       Impact factor: 11.527

5.  scRNA-seq of human vitiligo reveals complex networks of subclinical immune activation and a role for CCR5 in Treg function.

Authors:  Kyle J Gellatly; James P Strassner; Kingsley Essien; Maggi Ahmed Refat; Rachel L Murphy; Anthony Coffin-Schmitt; Amit G Pandya; Andrea Tovar-Garza; Michael L Frisoli; Xueli Fan; Xiaolan Ding; Evangeline E Kim; Zainab Abbas; Patrick McDonel; Manuel Garber; John E Harris
Journal:  Sci Transl Med       Date:  2021-09-08       Impact factor: 17.956

6.  Resident Memory and Recirculating Memory T Cells Cooperate to Maintain Disease in a Mouse Model of Vitiligo.

Authors:  Jillian M Richmond; James P Strassner; Mehdi Rashighi; Priti Agarwal; Madhuri Garg; Kingsley I Essien; Lila S Pell; John E Harris
Journal:  J Invest Dermatol       Date:  2018-11-10       Impact factor: 8.551

7.  Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo.

Authors:  Jillian M Richmond; James P Strassner; Lucio Zapata; Madhuri Garg; Rebecca L Riding; Maggi A Refat; Xueli Fan; Vincent Azzolino; Andrea Tovar-Garza; Naoya Tsurushita; Amit G Pandya; J Yun Tso; John E Harris
Journal:  Sci Transl Med       Date:  2018-07-18       Impact factor: 17.956

Review 8.  Chemical Vitiligo: A Subset of Vitiligo.

Authors:  Sanjay Ghosh
Journal:  Indian J Dermatol       Date:  2020 Nov-Dec       Impact factor: 1.494

9.  Reliability and validity of the Vitiligo Signs of Activity Score (VSAS).

Authors:  N van Geel; T Passeron; A Wolkerstorfer; R Speeckaert; K Ezzedine
Journal:  Br J Dermatol       Date:  2020-03-29       Impact factor: 9.302

10.  Altered circulating memory T cells in vitiligo cases followed NB-UVB therapy.

Authors:  Fuquan Lin; Xiukun Sun; Jiehao Lei; Ai-E Xu
Journal:  Photodermatol Photoimmunol Photomed       Date:  2021-07-27       Impact factor: 3.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.